Dement Geriatr Cogn Disord 2007;23:251–267

Treatment of Dementia in Parkinsonian Syndromes with Cholinesterase Inhibitors

Liepelt I.a · Maetzler W.a · Blaicher H.-P.b · Gasser T.a · Berg D.a
aHertie Institute for Clinical Brain Research and bDepartment of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
email Corresponding Author

 goto top of outline Key Words

  • Dementia
  • Parkinsonian syndromes
  • Cholinesterase inhibitor

 goto top of outline Abstract

In Parkinsonian syndromes behavioural symptoms and dementia can be even more debilitating than motor symptoms and are an important predictor for nursing home placement and mortality. Neuropathologically, dementia seems to be primarily related to cortical changes rather than to subcortical alterations. Concerning neurotransmitter systems, the cholinergic system has been proposed to play a key role in cognitive disturbances. Based on studies with patients with Alzheimer disease, the application of cholinesterase inhibitors is vividly discussed also for dementia associated with parkinsonian syndromes. This review focuses on the specific symptoms of dementia in different parkinsonian syndromes and critically questions the effect of cholinergic treatment on cognitive functions in patients with extrapyramidal syndromes and dementia. There is evidence that medication with some cholinesterase inhibitors can enhance cognition as well as activities of daily living in dementia with Parkinson’s disease and seems to reduce behavioural disturbances in both dementia with Parkinson’s disease and dementia with Lewy bodies. The effect of treatment with cholinesterase inhibitors in progressive supranuclear palsy and corticobasal degeneration warrants carefully designed studies including a sufficient number of patients and symptom-adopted dementia scales.

Copyright © 2007 S. Karger AG, Basel

 goto top of outline References
  1. Levy G, Tang MX, Louis ED, Cote LJ, Alfaro B, Mejia H, Stern Y, Marder K: The association of incident dementia with mortality in PD. Neurology 2002;59:1708–1713.
  2. Hughes TA, Ross HF, Mindham RH, Spokes EG: Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand 2004;110:118–123.
  3. Schrag A, Jahanshahi M, Quinn N: What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 2000;69:308–312.
  4. Jellinger K, Danielczyk W, Fischer P, Gabriel E: Clinicopathological analysis of dementia disorders in the elderly. J Neurol Sci 1990;95:239–258.
  5. Jellinger KA: Age-associated prevalence and risk factors of Lewy body pathology in a general population. Acta Neuropathol (Berl) 2003;106:383–384.
  6. Quinn NP: How to diagnose multiple system atrophy. Mov Disord 2005;20(suppl 12):S5–S10.

    External Resources

  7. Bruni AC, Takahashi-Fujigasaki J, Maltecca F, Foncin JF, Servadio A, Casari G, D’Adamo P, Maletta R, Curcio SA, De Michele G, Filla A, El Hachimi KH, Duyckaerts C: Behavioral disorder, dementia, ataxia, and rigidity in a large family with TATA box-binding protein mutation. Arch Neurol 2004;61:1314–1320.
  8. Reynolds NC Jr: The diagnosis of Huntington’s disease. Neurology 1987;37:1091.
  9. Willemsen R, Mientjes E, Oostra BA: FXTAS: a progressive neurologic syndrome associated with Fragile X premutation. Curr Neurol Neurosci Rep 2005;5:405–410.
  10. Kertesz A: The clinical spectrum of dementia in movement disorders; in Bedard MA, Agid Y, Chouinard S, Fahn S, Korczyn AD, Lesperance P (eds): Mental and Behavioral Dysfunction in Movement Disorders. Totwa, Humana Press, 2003, pp 223–229.
  11. Fuchs GA, Gemende I, Herting B, Lemke MR, Oehlwein C, Reichmann H, Rieke J, Emmans D, Volkmann J: Dementia in idiopathic Parkinson’s syndrome. J Neurol 2004;251(suppl 6):28–32.
  12. Harding AJ, Halliday GM: Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 2001;102:355–363.
  13. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C: Neuropathology of dementia in Parkinson’s disease: a prospective, community-based study. Ann Neurol 2005;58:773–776.
  14. Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA: Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson’s disease. Mov Disord 2003;18:81–86.
  15. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE: Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 2000;54:1916–1921.
  16. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, Thal LJ, Corey-Bloom J: Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407–411.
  17. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD: Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65:1716–1722.
  18. Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M, Asahina M, Hattori T, Tanada S, Irie T: In vivo mapping of brain cholinergic function in Parkinson’s disease and progressive supranuclear palsy. Adv Neurol 2001;86:249–255.
  19. Zgaljardic DJ, Foldi NS, Borod JC: Cognitive and behavioral dysfunction in Parkinson’s disease: neurochemical and clinicopathological contributions. J Neural Transm 2004;111:1287–1301.
  20. Pillon B, Czernecki V, Dubois B: Dopamine and cognitive function. Curr Opin Neurol 2003;16(suppl 2):S17–S22.

    External Resources

  21. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST: Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745–1748.
  22. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ: Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review) – Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:966–1002.
  23. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA: In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol 1996;40:399–410.
  24. Litvan I: Cholinergic approaches to the treatment of progressive supranuclear palsy. J Neural Transm Suppl 1994;42:275–281.
  25. Litvan I, Blesa R, Clark K, Nichelli P, Atack JR, Mouradian MM, Grafman J, Chase TN: Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol 1994;36:55–61.
  26. Atack JR, Litvan I, Thal LJ, May C, Rapoport SI, Chase TN: Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine. J Neurol Neurosurg Psychiatry 1991;54:832–835.
  27. Kasashima S, Oda Y: Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol (Berl) 2003;105:117–124.
  28. Liberini P, Valerio A, Memo M, Spano PF: Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer’s disease? Trends Pharmacol Sci 1996;17:155–160.
  29. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, Fairbairn AF, Ince PG, Morris CM, Cheng AV: Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993;7:69–79.
  30. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, Warren K, Jeste DV: Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000;15:794–802.
  31. Maidment ID, Fox C, Boustani M: A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson’s disease dementia. Acta Psychiatr Scand 2005;111:403–409.
  32. McKeith IG, Wesnes KA, Perry E, Ferrara R: Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004;18:94–100.
  33. Simard M, van Reekum R: The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 2004;16:409–425.
  34. Warren NM, Piggott MA, Perry EK, Burn DJ: Cholinergic systems in progressive supranuclear palsy. Brain 2005;128:239–249.
  35. Wild R, Pettit T, Burns A: Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 2003:CD003672.
  36. Maidment I, Fox C, Boustani M: Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev 2006:CD004747.
  37. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R: Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005;65:1654–1656.
  38. Kertzman C, Robinson DL, Litvan I: Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol 1990;47:1346–1350.
  39. Fogelson N, Kogan E, Korczyn AD, Giladi N, Shabtai H, Neufeld MY: Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neurol Scand 2003;107:252–255.
  40. Lebert F, Pasquier F, Souliez L, Petit H: Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry 1998;13:516–519.
  41. Wilcock GK, Scott MI: Tacrine for senile dementia of Alzheimer’s or Lewy body type. Lancet 1994;344:544.
  42. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P: Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 2001;56:730–736.
  43. Hobson P, Meara J: Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord 2004;19:1043–1049.
  44. Bonelli SB, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M: L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 2004;63:376–378.
  45. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P: Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387–392.
  46. Green J, McDonald WM, Vitek JL, Evatt M, Freeman A, Haber M, Bakay RA, Triche S, Sirockman B, DeLong MR: Cognitive impairments in advanced PD without dementia. Neurology 2002;59:1320–1324.
  47. Jacobs DM, Marder K, Cote LJ, Sano M, Stern Y, Mayeux R: Neuropsychological characteristics of preclinical dementia in Parkinson’s disease. Neurology 1995;45:1691–1696.
  48. Allain H, Lieury A, Thomas V, Reymann JM, Gandon JM, Belliard S: Explicit and procedural memory in Parkinson’s disease. Biomed Pharmacother 1995;49:179–186.
  49. Gilbert B, Belleville S, Bherer L, Chouinard S: Study of verbal working memory in patients with Parkinson’s disease. Neuropsychology 2005;19:106–114.
  50. Whittington CJ, Podd J, Kan MM: Recognition memory impairment in Parkinson’s disease: power and meta-analyses. Neuropsychology 2000;14:233–246.
  51. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, Spokes EG: A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 2000;54:1596–1602.
  52. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW: Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102–112.
  53. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K: Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 2004;318:121–134.
  54. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA: Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005;64:1404–1410.
  55. Hu MT, White SJ, Chaudhuri KR, Morris RG, Bydder GM, Brooks DJ: Correlating rates of cerebral atrophy in Parkinson’s disease with measures of cognitive decline. J Neural Transm 2001;108:571–580.
  56. Summerfield C, Junque C, Tolosa E, Salgado-Pineda P, Gomez-Anson B, Marti MJ, Pastor P, Ramirez-Ruiz B, Mercader J: Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 2005;62:281–285.
  57. Burton EJ, McKeith IG, Burn DJ, Williams ED, O’Brien JT: Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies and controls. Brain 2004;127:791–800.
  58. Nagano-Saito A, Washimi Y, Arahata Y, Kachi T, Lerch JP, Evans AC, Dagher A, Ito K: Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005;64:224–229.
  59. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, Mathis C, Davis JG, Moore RY, DeKosky ST: Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 2006;253:242–247.
  60. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004;351:2509–2518.
  61. Aarsland D, Laake K, Larsen JP, Janvin C: Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708–712.
  62. Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T: Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934–939.
  63. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L: Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry 2004;19:1–8.
  64. Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, Pakrasi S, Richardson J, Sanders J, McKeith IG: A comparison of the efficacy of donepezil in Parkinson’s disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005;20:938–944.
  65. Aarsland D, Hutchinson M, Larsen JP: Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry 2003;18:937–941.
  66. Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, Lane R: Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov Disord 2006;21:456–461.
  67. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD: Rivastigmine (Exelon) for dementia in patients with Parkinson’s disease. Acta Neurol Scand 2003;108:368–373.
  68. Hutchinson M, Fazzini E: Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1996;61:324–325.
  69. Minett TS, Thomas A, Wilkinson LM, Daniel SL, Sanders J, Richardson J, Littlewood E, Myint P, Newby J, McKeith IG: What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry 2003;18:988–993.
  70. Reading PJ, Luce AK, McKeith IG: Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001;16:1171–1174.
  71. Werber EA, Rabey JM: The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson’s disease and dementia. J Neural Transm 2001;108:1319–1325.
  72. Putt ME, Ravina B: Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson’s disease. Control Clin Trials 2002;23:111–126.
  73. Turner RS, D’Amato CJ, Chervin RD, Blaivas M: The pathology of REM sleep behavior disorder with comorbid Lewy body dementia. Neurology 2000;55:1730–1732.
  74. Del Ser T, McKeith I, Anand R, Cicin-Sain A, Ferrara R, Spiegel R: Dementia with lewy bodies: findings from an international multicentre study. Int J Geriatr Psychiatry 2000;15:1034–1045.
  75. Holmes C, Cairns N, Lantos P, Mann A: Validity of current clinical criteria for Alzheimer’s disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999;174:45–50.
  76. McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005;65:1863–1872.
  77. McKeith IG, Ballard CG, Perry RH, Ince PG, O’Brien JT, Neill D, Lowery K, Jaros E, Barber R, Thompson P, Swann A, Fairbairn AF, Perry EK: Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050–1058.
  78. Geser F, Wenning GK, Poewe W, McKeith I: How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 2005;20(suppl 12):S11–S20.
  79. Aarsland D, Ballard CG, Halliday G: Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004;17:137–145.
  80. Lambon Ralph MA, Powell J, Howard D, Whitworth AB, Garrard P, Hodges JR: Semantic memory is impaired in both dementia with Lewy bodies and dementia of Alzheimer’s type: a comparative neuropsychological study and literature review. J Neurol Neurosurg Psychiatry 2001;70:149–156.
  81. Serrano C, Garcia-Borreguero D: Fluctuations in cognition and alertness in Parkinson’s disease and dementia. Neurology 2004;63:S31–S34.
  82. Ballard CG, Ayre G, O’Brien J, Sahgal A, McKeith IG, Ince PG, Perry RH: Simple standardised neuropsychological assessments aid in the differential diagnosis of dementia with Lewy bodies from Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord 1999;10:104–108.
  83. Calderon J, Perry RJ, Erzinclioglu SW, Berrios GE, Dening TR, Hodges JR: Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2001;70:157–164.
  84. Galasko D: Lewy bodies and dementia. Curr Neurol Neurosci Rep 2001;1:435–441.
  85. Marui W, Iseki E, Nakai T, Miura S, Kato M, Ueda K, Kosaka K: Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci 2002;195:153–159.
  86. Hansen LA, Samuel W: Criteria for Alzheimer’s disease and the nosology of dementia with Lewy bodies. Neurology 1997;48:126–132.
  87. Dickson DW, Ruan D, Crystal H, Mark MH, Davies P, Kress Y, Yen SH: Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer’s disease: light and electron microscopic immunocytochemistry of CA2–3 neurites specific to DLBD. Neurology 1991;41:1402–1409.
  88. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O’Brien JT: MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer’s disease. Int J Geriatr Psychiatry 2000;15:911–916.
  89. O’Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, Gholkar A, Crum WR, Rossor MN, Fox NC: Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 2001;56:1386–1388.
  90. Colloby SJ, Fenwick JD, Williams ED, Paling SM, Lobotesis K, Ballard C, McKeith I, O’Brien JT: A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer’s disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging 2002;29:615–622.
  91. Pantel J, Schonknecht P, Essig M, Schroder J: Distribution of cerebral atrophy assessed by magnetic resonance imaging reflects patterns of neuropsychological deficits in Alzheimer’s dementia. Neurosci Lett 2004;361:17–20.
  92. Ishii K, Hosaka K, Mori T, Mori E: Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies. Ann Nucl Med 2004;18:447–451.
  93. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, Persad C, Heumann M, Wernette K: Differentiation of Alzheimer’s disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol 2005;191(suppl 1):S95–S103.

    External Resources

  94. Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, McKeith IG, O’Brien JT: Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001;56:643–649.
  95. Shimizu S, Hanyu H, Kanetaka H, Iwamoto T, Koizumi K, Abe K: Differentiation of dementia with Lewy bodies from Alzheimer’s disease using brain SPECT. Dement Geriatr Cogn Disord 2005;20:25–30.
  96. Donnemiller E, Heilmann J, Wenning GK, Berger W, Decristoforo C, Moncayo R, Poewe W, Ransmayr G: Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320–325.
  97. Colloby SJ, O’Brien JT, Fenwick JD, Firbank MJ, Burn DJ, McKeith IG, Williams ED: The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer’s disease and Parkinson’s disease. Neuroimage 2004;23:956–966.
  98. Samuel W, Alford M, Hofstetter CR, Hansen L: Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 1997;56:499–508.
  99. Ballard C, Piggott M, Johnson M, Cairns N, Perry R, McKeith I, Jaros E, O’Brien J, Holmes C, Perry E: Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000;48:868–876.
  100. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G: Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci 2002;23:41–43.
  101. Kurita A, Ochiai Y, Kono Y, Suzuki M, Inoue K: The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson’s disease. J Geriatr Psychiatry Neurol 2003;16:184–188.
  102. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos MJ, O’Brien J, Playfer J, Reid W: Dementia with Lewy bodies. Lancet Neurol 2004;3:19–28.
  103. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–2036.
  104. Beversdorf DQ, Warner JL, Davis RA, Sharma UK, Nagaraja HN, Scharre DW: Donepezil in the treatment of dementia with Lewy bodies. Am J Geriatr Psychiatry 2004;12:542–544.
  105. Querfurth HW, Allam GJ, Geffroy MA, Schiff HB, Kaplan RF: Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. Dement Geriatr Cogn Disord 2000;11:314–321.
  106. Edwards KR, Hershey L, Wray L, Bednarczyk EM, Lichter D, Farlow M, Johnson S: Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriatr Cogn Disord 2004;17(suppl 1):40–48.
  107. Grace JB, Walker MP, McKeith IG: A comparison of sleep profiles in patients with dementia with Lewy bodies and Alzheimer’s disease. Int J Geriatr Psychiatry 2000;15:1028–1033.
  108. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, Cicin-Sain A, Anand R, Spiegel R: Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 2002;13:183–192.
  109. McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK: Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000;15:387–392.
  110. Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ, Butler S, Wilkinson D, Woolford J, Waite J, McKeith IG: Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001;13:199–205.
  111. McKeith IG, Galasko D, Kosaka K, et al: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–1124.
  112. Rehman HU: Progressive supranuclear palsy. Postgrad Med J 2000;76:333–336.
  113. Poewe W, Wenning G: The differential diagnosis of Parkinson’s disease. Eur J Neurol 2002;9(suppl 3):23–30.
  114. Menza MA, Cocchiola J, Golbe LI: Psychiatric symptoms in progressive supranuclear palsy. Psychosomatics 1995;36:550–554.
  115. Millar D, Griffiths P, Zermansky AJ, Burn DJ: Characterizing behavioral and cognitive dysexecutive changes in progressive supranuclear palsy. Mov Disord 2006;21:199–207.
  116. Esmonde T, Giles E, Gibson M, Hodges JR: Neuropsychological performance, disease severity, and depression in progressive supranuclear palsy. J Neurol 1996;243:638–643.
  117. Birdi S, Rajput AH, Fenton M, Donat JR, Rozdilsky B, Robinson C, Macaulay R, George D: Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 2002;17:1255–1264.
  118. Dubois B, Slachevsky A, Pillon B, Beato R, Villalponda JM, Litvan I: ‘Applause sign’ helps to discriminate PSP from FTD and PD. Neurology 2005;64:2132–2133.
  119. Litvan I: Cognitive disturbances in progressive supranuclear palsy. J Neural Transm Suppl 1994;42:69–78.
  120. Pillon B, Dubois B, Lhermitte F, Agid Y: Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson’s disease, and Alzheimer’s disease. Neurology 1986;36:1179–1185.
  121. Bak TH, Crawford LM, Hearn VC, Mathuranath PS, Hodges JR: Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase 2005;11:268–273.
  122. Lange KW, Tucha O, Alders GL, Preier M, Csoti I, Merz B, Mark G, Herting B, Fornadi F, Reichmann H, Vieregge P, Reiners K, Becker G, Naumann M: Differentiation of parkinsonian syndromes according to differences in executive functions. J Neural Transm 2003;110:983–995.
  123. Zadikoff C, Lang AE: Apraxia in movement disorders. Brain 2005;128:1480–1497.
  124. Soliveri P, Piacentini S, Paridi D, Testa D, Carella F, Girotti F: Distal-proximal differences in limb apraxia in corticobasal degeneration but not progressive supranuclear palsy. Neurol Sci 2003;24:213–214.
  125. Pharr V, Uttl B, Stark M, Litvan I, Fantie B, Grafman J: Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology 2001;56:957–963.
  126. Soliveri P, Piacentini S, Girotti F: Limb apraxia and cognitive impairment in progressive supranuclear palsy. Neurocase 2005;11:263–267.
  127. Papapetropoulos S, Gonzalez J, Mash DC: Natural history of progressive supranuclear palsy: a clinicopathologic study from a population of brain donors. Eur Neurol 2005;54:1–9.
  128. Arai T, Ikeda K, Akiyama H, Shikamoto Y, Tsuchiya K, Yagishita S, Beach T, Rogers J, Schwab C, McGeer PL: Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick’s disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol (Berl) 2001;101:167–173.
  129. Brenneis C, Seppi K, Schocke M, Benke T, Wenning GK, Poewe W: Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2004;75:246–249.
  130. Cervos-Navarro J, Schumacher K: Neurofibrillary pathology in progressive supranuclear palsy (PSP). J Neural Transm Suppl 1994;42:153–164.
  131. Verny M, Duyckaerts C, Agid Y, Hauw JJ: The significance of cortical pathology in progressive supranuclear palsy: clinico-pathological data in 10 cases. Brain 1996;119:1123–1136.
  132. Cordato NJ, Pantelis C, Halliday GM, Velakoulis D, Wood SJ, Stuart GW, Currie J, Soo M, Olivieri G, Broe GA, Morris JG: Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 2002;125:789–800.
  133. Bigio EH, Brown DF, White CL 3rd: Progressive supranuclear palsy with dementia: cortical pathology. J Neuropathol Exp Neurol 1999;58:359–364.
  134. Cordato NJ, Halliday GM, Harding AJ, Hely MA, Morris JG: Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann Neurol 2000;47:718–728.
  135. Albert ML, Feldman RG, Willis AL: The ‘subcortical dementia’ of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974;37:121–130.
  136. Kompoliti K, Goetz CG, Litvan I, Jellinger K, Verny M: Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998;55:1099–1102.
  137. Nardone R, Florio I, Lochner P, Tezzon F: Cholinergic cortical circuits in Parkinson’s disease and in progressive supranuclear palsy: a transcranial magnetic stimulation study. Exp Brain Res 2005;163:128–131.
  138. Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T: Brain muscarinic receptors in progressive supranuclear palsy and Parkinson’s disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry 1998;65:155–163.
  139. Litvan I, Gomez C, Atack JR, Gillespie M, Kask AM, Mouradian MM, Chase TN: Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 1989;26:404–407.
  140. Blin J, Mazetti P, Mazoyer B, Rivaud S, Ben Ayed S, Malapani C, Pillon B, Agid Y: Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy? Brain 1995;118:1485–1495.
  141. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A: Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001;57:467–473.
  142. Fabbrini G, Barbanti P, Bonifati V, Colosimo C, Gasparini M, Vanacore N, Meco G: Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand 2001;103:123–125.
  143. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ: The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861–870.
  144. Kompoliti K, Goetz CG, Boeve BF, Maraganore DM, Ahlskog JE, Marsden CD, Bhatia KP, Greene PE, Przedborski S, Seal EC, Burns RS, Hauser RA, Gauger LL, Factor SA, Molho ES, Riley DE: Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998;55:957–961.
  145. Watts RL, Mirra SS, Richardson EP: Corticobasal ganglionic degeneration; in Marsden CD, Fahn S (eds): Movement Disorders 3. Oxford, Butterworth-Heinemann, 1994, pp 282–299.
  146. Lang AE: Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord 2005;20(suppl 12):S83–S91.

    External Resources

  147. Doody RS, Jankovic J: The alien hand and related signs. J Neurol Neurosurg Psychiatry 1992;55:806–810.
  148. Ozsancak C, Auzou P, Hannequin D: Dysarthria and orofacial apraxia in corticobasal degeneration. Mov Disord 2000;15:905–910.
  149. Thumler BH, Urban PP, Davids E, Siessmeier M, Schreckenberger T, Benz P, Stoeter P, Bartenstein P, Hopf HC: Dysarthria and pathological laughter/crying as presenting symptoms of corticobasal-ganglionic degeneration syndrome. J Neurol 2003;250:1107–1108.
  150. Vanek Z, Jankovic J: Dystonia in corticobasal degeneration. Mov Disord 2001;16:252–257.
  151. Rivaud-Pechoux S, Vidailhet M, Gallouedec G, Litvan I, Gaymard B, Pierrot-Deseilligny C: Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology 2000;54:1029–1032.
  152. Leiguarda R, Lees AJ, Merello M, Starkstein S, Marsden CD: The nature of apraxia in corticobasal degeneration. J Neurol Neurosurg Psychiatry 1994;57:455–459.
  153. Leiguarda R, Merello M, Balej J: Apraxia in corticobasal degeneration. Adv Neurol 2000;82:103–121.
  154. Leiguarda RC, Pramstaller PP, Merello M, Starkstein S, Lees AJ, Marsden CD: Apraxia in Parkinson’s disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain 1997;120:75–90.
  155. Grimes DA, Lang AE, Bergeron CB: Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999;53:1969–1974.
  156. Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS: Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 1997;48:959–969.
  157. Kertesz A, Martinez-Lage P, Davidson W, Munoz DG: The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000;55:1368–1375.
  158. Ferrer I, Hernandez I, Boada M, Llorente A, Rey MJ, Cardozo A, Ezquerra M, Puig B: Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies. Acta Neuropathol (Berl) 2003;106:419–435.
  159. Kertesz A, Munoz D: Relationship between frontotemporal dementia and corticobasal degeneration/progressive supranuclear palsy. Dement Geriatr Cogn Disord 2004;17:282–286.
  160. Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG: The evolution and pathology of frontotemporal dementia. Brain 2005;128:1996–2005.
  161. Mimura M, White RF, Albert ML: Corticobasal degeneration: neuropsychological and clinical correlates. J Neuropsychiatry Clin Neurosci 1997;9:94–98.
  162. Frattali CM, Grafman J, Patronas N, Makhlouf F, Litvan I: Language disturbances in corticobasal degeneration. Neurology 2000;54:990–992.
  163. Dubois B, Slachevsky A, Litvan I, Pillon B: The FAB: a Frontal Assessment Battery at bedside. Neurology 2000;55:1621–1626.
  164. Graham NL, Bak TH, Hodges JR: Corticobasal degeneration as a cognitive disorder. Mov Disord 2003;18:1224–1232.
  165. Graham NL, Zeman A, Young AW, Patterson K, Hodges JR: Dyspraxia in a patient with corticobasal degeneration: the role of visual and tactile inputs to action. J Neurol Neurosurg Psychiatry 1999;67:334–344.
  166. Pillon B, Blin J, Vidailhet M, Deweer B, Sirigu A, Dubois B, Agid Y: The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer’s disease. Neurology 1995;45:1477–1483.
  167. Le Rhun E, Richard F, Pasquier F: Natural history of primary progressive aphasia. Neurology 2005;65:887–891.
  168. Litvan I, Cummings JL, Mega M: Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998;65:717–721.
  169. Soliveri P, Monza D, Paridi D, Carella F, Genitrini S, Testa D, Girotti F: Neuropsychological follow-up in patients with Parkinson’s disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2000;69:313–318.
  170. Groschel K, Hauser TK, Luft A, Patronas N, Dichgans J, Litvan I, Schulz JB: Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage 2004;21:714–724.
  171. Sobrido MJ, Abu-Khalil A, Weintraub S, Johnson N, Quinn B, Cummings JL, Mesulam MM, Geschwind DH: Possible association of the tau H1/H1 genotype with primary progressive aphasia. Neurology 2003;60:862–864.
  172. Arvanitakis Z, Wszolek ZK: Recent advances in the understanding of tau protein and movement disorders. Curr Opin Neurol 2001;14:491–497.
  173. Feany MB, Mattiace LA, Dickson DW: Neuropathologic overlap of progressive supranuclear palsy, Pick’s disease and corticobasal degeneration. J Neuropathol Exp Neurol 1996;55:53–67.
  174. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A: Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 2004;21:931–937.
  175. Geula C, Darvesh S: Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer’s disease. Drugs Today (Barc) 2004;40:711–721.
  176. Gomez-Ramos P, Moran MA: Ultrastructural localization of butyrylcholinesterase in senile plaques in the brains of aged and Alzheimer disease patients. Mol Chem Neuropathol 1997;30:161–173.

 goto top of outline Author Contacts

Inga Liepelt, Hertie Institute for Clinical Brain Research
Department of Neurodegenerative Diseases
Hoppe-Seyler Strasse 3, DE–72076 Tübingen (Germany)
Tel. +49 7071, ext. 2980 424, Fax +49 7071 2948

 goto top of outline Article Information

Accepted: November 25, 2006
Published online: March 26, 2007
Number of Print Pages : 17
Number of Figures : 0, Number of Tables : 5, Number of References : 176

 goto top of outline Publication Details

Dementia and Geriatric Cognitive Disorders

Vol. 23, No. 6, Year 2007 (Cover Date: May 2007)

Journal Editor: Chan-Palay, V. (New York, N.Y.)
ISSN: 1420–8008 (print), 1421–9824 (Online)

For additional information:

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.